For the quarter ending 2025-09-30, VOR made $33,987K in revenue. -$812,686K in net income. Net profit margin of -2391.17%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 14,142 | 261,499 | ||
| General and administrative | 13,965 | 12,785 | ||
| Total operating expenses | 28,107 | 274,284 | ||
| Loss from operations | -28,107 | -274,284 | ||
| Interest income | 1,731 | 537 | ||
| Other income | 4,149 | - | ||
| Change in fair value of warrant liabilities | 790,457 | 1,299,922 | ||
| Total other (expense) income | -784,577 | -1,299,385 | ||
| Net loss | -812,684 | -1,573,669 | ||
| Unrealized (loss) gain on available for sale marketable securities | -2 | -9 | ||
| Total other comprehensive (loss) income | -2 | -9 | ||
| Comprehensive loss | -812,686 | -1,573,678 | ||
| Earnings per share, basic, total | -121.63 | -12.56 | ||
| Net loss per share attributable to common stockholders, diluted | -121.63 | -12.56 | ||
| Weighted-average number of common shares outstanding, basic | 6,681,794 | 125,271,447 | ||
| Weighted-average number of common shares outstanding, diluted | 6,681,794 | 125,271,447 | ||
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)